The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Precision medicine is about matching the right drugs to the right patients. Although this
approach is technology agnostic, in cancer there is a tendency to make precision medicine …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Multidrug resistance (MDR) is a serious problem that hampers the success of cancer
pharmacotherapy. A common mechanism is the overexpression of ATP-binding cassette …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

BACKGROUND A frequent complication of anticancer treatment, oral and gastrointestinal
(GI) mucositis, threatens the effectiveness of therapy because it leads to dose reductions …

Protein kinases have grown over the past few years as a crucial target for different cancer
types. With the multifactorial nature of cancer, and the fast development of drug resistance …

In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg,
Mariano Barbacid and many others in identifying cancer-causing genes in humans was …

Multi-drug resistance (MDR) developed in response to chemotherapy is one of the
prominent causes of therapeutic failure. The major underlying factors that contribute to such …